scholarly journals Successful unrelated donor stem cell transplantation for advanced myelofibrosis in an adult patient with history of orthotopic liver transplantation

Haematologica ◽  
2009 ◽  
Vol 94 (4) ◽  
pp. 594-596 ◽  
Author(s):  
J. B. Perz ◽  
U. Hegenbart ◽  
N. Kroeger ◽  
G. Otto ◽  
A. D. Ho ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Adult Patient ◽  
Cell Transplantation ◽  
Orthotopic Liver Transplantation ◽  
Unrelated Donor ◽  
History Of

scholarly journals Timing of allogeneic stem cell transplantation for myelodysplastic syndromes and aplastic anemia

Hematology ◽  
2014 ◽  
Vol 2014 (1) ◽  
pp. 77-81 ◽  
Author(s):  
Corey Cutler
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Aplastic Anemia ◽  
Cell Transplantation ◽  
Significant Risk ◽  
Unrelated Donor ◽  
Hematopoietic Stem ◽  
Matched Sibling ◽  
Disease Modifying ◽  
Disease Modifying Agents

Abstract Allogeneic hematopoietic stem cell transplantation (HSCT) for myelodysplastic syndrome (MDS) is a potentially curative procedure, but is associated with a significant risk of morbidity and mortality. With the recent approval of disease-modifying agents, the appropriate timing of allogeneic HSCT needs to be addressed. Similarly, the optimal use of these disease-modifying agents before HSCT needs to be determined. In severe aplastic anemia, HSCT is a proven cure, but HLA-matched sibling donors are found in fewer than 25% of newly diagnosed patients. The use of early unrelated donor HSCT is an evolving concept that will become more accepted as improvements in HSCT outcomes continue.

Sign in / Sign up

Export Citation Format

Share Document